NLM Digital Collections

Search

Start Over Subjects Prescription Drugs -- economics ✖Remove constraint Subjects: Prescription Drugs -- economics

3. Assessing user fees under the Prescription Drug User Fee Amendments of 2017

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, May 2018
Subject(s):
Fees and Charges
Investigational New Drug Application -- economics
Prescription Drugs -- economics
Biological Products -- economics
Orphan Drug Production -- economics
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

4. The Medi-Cal prescription drug benefit: an overview

Publication:
Oakland, Calif. : California HealthCare Foundation, [2009]
Subject(s):
Health Expenditures -- trends
Insurance Benefits
Insurance, Pharmaceutical Services
Medicaid
Prescription Drugs -- economics
Adult
Aged
Child
Cost Control
Cost Sharing
Disabled Persons
Drug Costs
Drug Utilization Review
Drugs, Generic
Fee-for-Service Plans
Forecasting
Managed Care Programs
Medicare Part D
Middle Aged
Humans
California

5. Status of U.S. health insurance coverage and the potential of recent congressional health reform bills to expand coverage and lower consumer costs: invited testimony : U.S. House of Representatives, Committee on Rules : hearing on "Medicare for All Act of 2019"

Author(s):
Collins, Sara R., author
Publication:
New York, NY : The Commonwealth Fund, April 30, 2019
Subject(s):
Insurance Coverage -- economics
Insurance Coverage -- legislation & jurisprudence
Insurance, Health -- economics
Insurance, Health -- legislation & jurisprudence
Financing, Personal
Forecasting
Health Benefit Plans, Employee -- economics
Health Benefit Plans, Employee -- statistics & numerical data
Health Benefit Plans, Employee -- trends
Health Care Costs -- trends
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Income
Insurance Coverage -- trends
Insurance, Health -- trends
Insurance, Health, Reimbursement
Medically Uninsured -- statistics & numerical data
Prescription Drugs -- economics
Humans
United States
United States.

6. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):
Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author
Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

7. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

8. Prescription drug spending by Medicare beneficiaries in institutional and residential settings, 1998-2001

Author(s):
Simoni-Wastila, Linda, author
Stuart, Bruce C., author
Shaffer, Thomas, author
Publication:
Washington, D.C. : Office of Disability, Aging, and Long-Term Care Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, [2007]
Subject(s):
Prescription Drugs -- economics
Prescription Fees -- statistics & numerical data
Aged
Assisted Living Facilities
Health Expenditures -- statistics & numerical data
Medicare Part D -- utilization
United States

9. Spending on shoppable services in health care

Author(s):
Frost, Amanda, author
Newman, David, author
Publication:
Washington, DC, : Health Care Cost Institute, March 2016
Subject(s):
Consumer Behavior
Health Care Costs -- statistics & numerical data
Health Expenditures -- statistics & numerical data
Arthroplasty, Replacement, Hip -- economics
Arthroplasty, Replacement, Knee -- economics
Deductibles and Coinsurance
Disclosure
Health Benefit Plans, Employee -- economics
Prescription Drugs -- economics
Humans
United States

10. Consumer-driven health plans: a cost and utilization analysis

Author(s):
Frost, Amanda, author
Kennedy, Kevin, author
Publication:
Washington, DC, : Health Care Cost Institute, September 2016
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Health Services -- utilization
Consumer Behavior
Adolescent
Adult
Child
Emergency Medical Services -- economics
Financing, Personal
Forecasting
Insurance, Health -- economics
Middle Aged
Prescription Drugs -- economics
Sex Factors
Humans
United States

11. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):
Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author
Publication:
[New York, N.Y.] : Commonwealth Fund, July 2017
Subject(s):
Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
Drug Industry -- economics
Drugs, Generic -- economics
Economic Competition
Legislation, Drug
Orphan Drug Production -- economics
Humans
United States

12. Does Medicare Part D protect the elderly from financial risk?

Author(s):
Englehardt, Gary V., author
Gruber, Jonathan, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, June 2011
Subject(s):
Financing, Personal
Health Services for the Aged -- economics
Insurance Coverage -- economics
Medicare Part D -- economics
Risk Sharing, Financial
Aged
Drug Costs
Forecasting
Health Care Surveys
Health Expenditures -- statistics & numerical data
Insurance Coverage -- statistics & numerical data
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Prescription Drugs -- economics
Socioeconomic Factors
Humans
United States

13. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Armstrong, Katrina A., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Antineoplastic Agents -- economics
Antineoplastic Agents -- therapeutic use
Drug Costs
Financing, Personal -- statistics & numerical data
Medication Adherence -- statistics & numerical data
Administration, Oral
Antineoplastic Agents -- administration & dosage
Health Services Accessibility
Prescription Drugs -- economics
Socioeconomic Factors
Time Factors
Humans
United States

16. Rx Watchdog report: comparative measures of price change for prescription drugs and other goods

Publication:
Washington, D.C. : AARP Public Policy Institute, c2009
Subject(s):
Drug Costs -- statistics & numerical data
Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- trends
Drugs, Generic -- economics
Forecasting
Health Expenditures -- trends
Inflation, Economic
Humans
United States

19. Rx price watch report: trends in retail prices of specialty prescription drugs widely used by Medicare beneficiaries : 2005 to 2009

Publication:
Washington, D.C. : AARP Public Policy Institute, c2012
Subject(s):
Drug Costs -- trends
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs -- statistics & numerical data
Drugs, Generic -- economics
Forecasting
Pharmaceutical Preparations -- economics
Humans
United States

21. Trends in prescription drug spending: 2016-2021

Author(s):
Parasrampuria, Sonal, author
Murphy, Stephen, (Of Office of Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation), author
Publication:
Washington, D.C. : Assistant Secretary for Planning and Evaluation, Office Of Science and Data Policy September 2022
Subject(s):
Health Expenditures -- trends
Prescription Drugs -- economics
United States

23. Summary of recent and proposed changes to Medicare prescription drug coverage and reimbursement

Author(s):
Cubanski, Juliette, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, February 2018
Subject(s):
Medicare Part B -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Formularies as Topic
Insurance, Health, Reimbursement -- economics
Medicare Part B -- legislation & jurisprudence
Medicare Part D -- legislation & jurisprudence
Humans
United States

32. A comparison of brand-name drug prices among selected federal programs

Author(s):
Baker, Colin, author
Laughery, Scott, author
Patel, Yash, author
Publication:
[Washington, DC] : Congressional Budget Office, February 2021
Subject(s):
Drug Costs -- statistics & numerical data
Government Programs -- economics
Medicaid -- economics
Federal Government
Medicare Part D -- economics
Prescription Drugs -- economics
United States
United States. Department of Defense.
United States. Department of Veterans Affairs.

47. One percent of drugs with Medicaid reimbursement were not FDA-approved

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, May 2019
Subject(s):
Drug Approval
Insurance, Health, Reimbursement -- economics
Insurance, Health, Reimbursement -- statistics & numerical data
Medicaid -- economics
Medicaid -- statistics & numerical data
Economics, Pharmaceutical
Fraud -- prevention & control
Prescription Drugs -- economics
Humans
United States
United States. Food and Drug Administration.

48. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019
Subject(s):
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Insurance, Health, Reimbursement -- statistics & numerical data
Insurance, Health, Reimbursement -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Economics, Pharmaceutical -- statistics & numerical data
Economics, Pharmaceutical -- trends
Forecasting
Prescription Drugs -- economics
Humans
United States

50. Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, September 19, 2023
Subject(s):
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Drugs -- economics
United States